Contact Us
Global Specific Antiviral Drugs For COVID 19 Market Report 2025

Specific Antiviral Drugs For COVID 19 Global Market Report 2025 - By Type (Tablet, Injection), By Indication (Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment), By Drug Class (Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies), By Route Of Administration (Oral, Intravenous, Subcutaneous, Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels) - Market Size, Trends, And Global Forecast 2025-2034

Specific Antiviral Drugs For COVID 19 Global Market Report 2025

Report Price : $4490.00 | Pages : 200 | Published : June 2025 | Delivery Time: 2-3 business days Info | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Specific Antiviral Drugs For COVID 19 Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

What Is Covered Under Specific Antiviral Drugs For COVID 19 Market?

Specific antiviral drugs for COVID-19 are medications designed to directly target and inhibit the replication or function of the SARS-CoV-2 virus, which causes COVID-19. These drugs help reduce the severity and duration of the infection by interfering with viral processes such as entry, replication, or assembly.

The main types of specific antiviral drugs for COVID-19 come in tablet and injection forms. Tablets are solid pharmaceutical dosage forms that contain a precise amount of active medicinal ingredient(s) along with excipients, compressed into a small, usually flat or oval shape. These antiviral drugs are indicated for use in hospitalized patients, non-hospitalized patients, and for preventive treatment. The drug classes include nucleoside analogues, Protease Inhibitors, RNA polymerase inhibitors, entry inhibitors, and monoclonal antibodies, and they are administered via various routes such as oral, intravenous, subcutaneous, and inhalation. These medications are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and other outlets.

Specific Antiviral Drugs For COVID 19 Market Size and growth rate 2025 to 2029: Graph

What Is The Specific Antiviral Drugs For COVID 19 Market Size 2025 And Growth Rate?

The specific antiviral drugs for covid 19 market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to rising hospitalization due to severe cases, increasing government funding for antiviral research, increasing demand for targeted therapeutics over generic treatments, rising awareness about early antiviral intervention, and increasing collaborations among pharmaceutical companies.

What Is The Specific Antiviral Drugs For COVID 19 Market Growth Forecast?

The specific antiviral drugs for covid 19 market size is expected to see rapid growth in the next few years. It will grow to $28.43 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, increasing number of clinical trials, growing demand for effective COVID-19 treatment options, increasing prevalence of COVID-19 variants, and growing acceptance of oral antiviral therapies. Major trends in the forecast period include innovation in broad-spectrum antiviral formulations, integration of artificial intelligence in drug discovery, advancement in personalized antiviral therapies, innovation in combination therapy approaches, and integration of genomic data to target viral mutations.

How Is The Specific Antiviral Drugs For COVID 19 Market Segmented?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

What Is Driving The Specific Antiviral Drugs For COVID 19 Market? Rise In COVID-19 Cases The Growth Of The Market Due To Increasing Demand For Antiviral Treatments

The rising number of COVID-19 cases is expected to propel the growth of the specific antiviral drugs for the COVID-19 market going forward. COVID-19 cases refer to individuals who tested positive for the SARS-CoV-2 virus, which causes COVID-19. The rising number of COVID-19 cases is due to the emergence of new variants that spread more easily and can partially evade immunity from vaccines or past infections. Specific antiviral drugs for COVID-19 help reduce the severity and duration of the illness, improving patient outcomes and lowering the overall burden of COVID-19 cases. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, on average, COVID-19 deaths that included additional causes of death had 4.5 contributing conditions listed in 2022, compared to 4.2 in 2021. Therefore, the rising number of COVID-19 cases drives the growth of the specific antiviral drugs for the COVID-19 market.

Who Are The Major Players In The Global Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

What Are The Key Trends Of The Global Specific Antiviral Drugs For COVID 19 Market? Oral Antiviral Innovations Enhance COVID-19 Treatment Accessibility And Effectiveness

Major companies operating in the specific antiviral drugs for the COVID-19 market are focusing on developing innovative therapies, such as oral antiviral therapies, to enhance treatment accessibility and effectiveness. Oral antiviral therapies are medications taken by mouth to inhibit the replication of viruses like COVID-19, offering a convenient and effective treatment option. For instance, in January 2022, Lupin Limited, an India-based pharmaceutical company, launched the antiviral drug Molnupiravir under the brand name Molnulup to treat high-risk adult patients with COVID-19. This oral medication is intended for adults with mild to moderate COVID-19 who are at risk of developing severe illness. Molnupiravir works by inhibiting the replication of the SARS-CoV-2 virus, thereby helping to lower the viral load and reduce the severity of the disease. It is most effective when started within five days of symptom onset and is especially beneficial for individuals with comorbid conditions such as obesity, advanced age, diabetes, or cardiovascular disease.

What Are Latest Mergers And Acquisitions In The Specific Antiviral Drugs For COVID 19 Market? GSK And Curevac Collaborate To Develop Innovative Mrna Vaccines For Influenza And COVID-19

In July 2024, GSK plc, a UK-based pharmaceutical company, collaborated with CureVac to develop and commercialize next-generation mRNA vaccines for COVID-19 and influenza. This collaboration aims to develop and commercialize innovative mRNA vaccines for influenza and COVID-19 to improve global public health outcomes. CureVac N.V. is a Germany-based company that develops therapies based on messenger RNA (mRNA) technology.

What Is The Regional Outlook For The Global Specific Antiviral Drugs For COVID 19 Market?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the specific antiviral drugs for covid 19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Specific Antiviral Drugs For COVID 19 Market?

The specific antiviral drugs for COVID-19 market consists of sales of host-directed antivirals, immunomodulators, fusion inhibitors, helicase inhibitors, and tmprss2 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Specific Antiviral Drugs For COVID 19 Industry?

The specific antiviral drugs for COVID-19 market research report is one of a series of new reports from The Business Research Company that cover specific antiviral drugs for COVID-19 market statistics, including the specific antiviral drugs for COVID-19 industry's global market size, regional shares, competitors with the specific antiviral drugs for COVID-19 market share, detailed specific antiviral drugs for COVID-19 market segments, market trends and opportunities, and any further data you may need to thrive in the specific antiviral drugs for COVID-19 market. This specific antiviral drugs for COVID-19 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Specific Antiviral Drugs For COVID 19 Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $15.23 billion
Revenue Forecast In 2034 $28.43 billion
Growth Rate CAGR of 16.9% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The specific antiviral drugs for covid 19 market covered in this report is segmented –
1) By Type: Tablet, Injection
2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment
3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies
4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments
1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets
2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Specific Antiviral Drugs For COVID 19 Market Characteristics

    3. Specific Antiviral Drugs For COVID 19 Market Trends And Strategies

    4. Specific Antiviral Drugs For COVID 19 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

    5. Global Specific Antiviral Drugs For COVID 19 Growth Analysis And Strategic Analysis Framework

    5.1. Global Specific Antiviral Drugs For COVID 19 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Specific Antiviral Drugs For COVID 19 Market Growth Rate Analysis

    5.4. Global Specific Antiviral Drugs For COVID 19 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Specific Antiviral Drugs For COVID 19 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Specific Antiviral Drugs For COVID 19 Total Addressable Market (TAM)

    6. Specific Antiviral Drugs For COVID 19 Market Segmentation

    6.1. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Tablet

    Injection

    6.2. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitalized Patients

    Non-Hospitalized Patients

    Preventive Treatment

    6.3. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Nucleoside Analogues

    Protease Inhibitors

    Ribonucleic Acid Polymerase Inhibitors

    Entry Inhibitors

    Monoclonal Antibodies

    6.4. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral

    Intravenous

    Subcutaneous

    Inhalation

    6.5. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Other Distribution Channels

    6.6. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Oral Antiviral Tablets

    Combination Antiviral Tablets

    Extended-Release Tablets

    6.7. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Intravenous (IV) Antiviral Injections

    Intramuscular (IM) Antiviral Injections

    Subcutaneous Antiviral Injections

    7. Specific Antiviral Drugs For COVID 19 Market Regional And Country Analysis

    7.1. Global Specific Antiviral Drugs For COVID 19 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Specific Antiviral Drugs For COVID 19 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market

    8.1. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Specific Antiviral Drugs For COVID 19 Market

    9.1. China Specific Antiviral Drugs For COVID 19 Market Overview

    9.2. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Specific Antiviral Drugs For COVID 19 Market

    10.1. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Specific Antiviral Drugs For COVID 19 Market

    11.1. Japan Specific Antiviral Drugs For COVID 19 Market Overview

    11.2. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Specific Antiviral Drugs For COVID 19 Market

    12.1. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Specific Antiviral Drugs For COVID 19 Market

    13.1. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Specific Antiviral Drugs For COVID 19 Market

    14.1. South Korea Specific Antiviral Drugs For COVID 19 Market Overview

    14.2. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Specific Antiviral Drugs For COVID 19 Market

    15.1. Western Europe Specific Antiviral Drugs For COVID 19 Market Overview

    15.2. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Specific Antiviral Drugs For COVID 19 Market

    16.1. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Specific Antiviral Drugs For COVID 19 Market

    17.1. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Specific Antiviral Drugs For COVID 19 Market

    18.1. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Specific Antiviral Drugs For COVID 19 Market

    19.1. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Specific Antiviral Drugs For COVID 19 Market

    20.1. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Specific Antiviral Drugs For COVID 19 Market

    21.1. Eastern Europe Specific Antiviral Drugs For COVID 19 Market Overview

    21.2. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Specific Antiviral Drugs For COVID 19 Market

    22.1. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Specific Antiviral Drugs For COVID 19 Market

    23.1. North America Specific Antiviral Drugs For COVID 19 Market Overview

    23.2. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Specific Antiviral Drugs For COVID 19 Market

    24.1. USA Specific Antiviral Drugs For COVID 19 Market Overview

    24.2. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Specific Antiviral Drugs For COVID 19 Market

    25.1. Canada Specific Antiviral Drugs For COVID 19 Market Overview

    25.2. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Specific Antiviral Drugs For COVID 19 Market

    26.1. South America Specific Antiviral Drugs For COVID 19 Market Overview

    26.2. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Specific Antiviral Drugs For COVID 19 Market

    27.1. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Specific Antiviral Drugs For COVID 19 Market

    28.1. Middle East Specific Antiviral Drugs For COVID 19 Market Overview

    28.2. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Specific Antiviral Drugs For COVID 19 Market

    29.1. Africa Specific Antiviral Drugs For COVID 19 Market Overview

    29.2. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape And Company Profiles

    30.1. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape

    30.2. Specific Antiviral Drugs For COVID 19 Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

    31. Specific Antiviral Drugs For COVID 19 Market Other Major And Innovative Companies

    31.1. GSK plc

    31.2. Eli Lilly and Company

    31.3. Gilead Sciences Inc.

    31.4. Regeneron Pharmaceuticals Inc

    31.5. Hetero Drugs Limited

    31.6. Sun Pharmaceutical Industries Limited

    31.7. Shionogi and Co. Ltd.

    31.8. Cipla Limited

    31.9. Beximco Pharmaceuticals Limited

    31.10. BioCryst Pharmaceuticals Inc.

    31.11. Atea Pharmaceuticals Inc.

    31.12. Enanta Pharmaceuticals Inc.

    31.13. RedHill Biopharma Ltd.

    31.14. Aligos Therapeutics Inc.

    31.15. Synairgen plc

    32. Global Specific Antiviral Drugs For COVID 19 Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Specific Antiviral Drugs For COVID 19 Market

    34. Recent Developments In The Specific Antiviral Drugs For COVID 19 Market

    35. Specific Antiviral Drugs For COVID 19 Market High Potential Countries, Segments and Strategies

    35.1 Specific Antiviral Drugs For COVID 19 Market In 2029 - Countries Offering Most New Opportunities

    35.2 Specific Antiviral Drugs For COVID 19 Market In 2029 - Segments Offering Most New Opportunities

    35.3 Specific Antiviral Drugs For COVID 19 Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Specific Antiviral Drugs For COVID 19 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Specific Antiviral Drugs For COVID 19 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Pfizer Inc. Financial Performance
  • Table 79: Johnson and Johnson Financial Performance
  • Table 80: Roche Holding AG Financial Performance
  • Table 81: Merck And Co. Inc. Financial Performance
  • Table 82: Novartis AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Specific Antiviral Drugs For COVID 19 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Specific Antiviral Drugs For COVID 19 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Pfizer Inc. Financial Performance
  • Figure 79: Johnson and Johnson Financial Performance
  • Figure 80: Roche Holding AG Financial Performance
  • Figure 81: Merck And Co. Inc. Financial Performance
  • Figure 82: Novartis AG Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Specific Antiviral Drugs For COVID 19 market?

Specific antiviral drugs for COVID-19 are medications designed to directly target and inhibit the replication or function of the SARS-CoV-2 virus, which causes COVID-19. These drugs help reduce the severity and duration of the infection by interfering with viral processes such as entry, replication, or assembly. For further insights on the Specific Antiviral Drugs For COVID 19 market, request a sample here

How will the Specific Antiviral Drugs For COVID 19 market drivers and restraints affect the market dynamics? What forces will shape the Specific Antiviral Drugs For COVID 19 industry going forward?

The Specific Antiviral Drugs For COVID 19 market major growth driver - Rise In COVID-19 Cases The Growth Of The Market Due To Increasing Demand For Antiviral Treatments. For further insights on the Specific Antiviral Drugs For COVID 19 market, request a sample here

What is the forecast market size or the forecast market value of the Specific Antiviral Drugs For COVID 19 market?

The Specific Antiviral Drugs For COVID 19 market size has grown strongly in recent years. The specific antiviral drugs for covid 19 market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to rising hospitalization due to severe cases, increasing government funding for antiviral research, increasing demand for targeted therapeutics over generic treatments, rising awareness about early antiviral intervention, and increasing collaborations among pharmaceutical companies. The specific antiviral drugs for covid 19 market size is expected to see rapid growth in the next few years. It will grow to $28.43 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, increasing number of clinical trials, growing demand for effective COVID-19 treatment options, increasing prevalence of COVID-19 variants, and growing acceptance of oral antiviral therapies. Major trends in the forecast period include innovation in broad-spectrum antiviral formulations, integration of artificial intelligence in drug discovery, advancement in personalized antiviral therapies, innovation in combination therapy approaches, and integration of genomic data to target viral mutations. For further insights on the Specific Antiviral Drugs For COVID 19 market, request a sample here

How is the Specific Antiviral Drugs For COVID 19 market segmented?

The specific antiviral drugs for covid 19 market covered in this report is segmented –
1) By Type: Tablet, Injection
2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment
3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies
4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels Subsegments
1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets
2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections For further insights on the Specific Antiviral Drugs For COVID 19 market,
request a sample here

Which region has the largest share of the Specific Antiviral Drugs For COVID 19 market? What are the other regions covered in the report?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Specific Antiviral Drugs For COVID 19 market, request a sample here.

Who are the major players in the Specific Antiviral Drugs For COVID 19 market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc . For further insights on the Specific Antiviral Drugs For COVID 19 market, request a sample here.

What are the key trends in the Specific Antiviral Drugs For COVID 19 market?

Major trends in the Specific Antiviral Drugs For COVID 19 market include Oral Antiviral Innovations Enhance COVID-19 Treatment Accessibility And Effectiveness. For further insights on the Specific Antiviral Drugs For COVID 19 market, request a sample here.

What are the major opportunities in the Specific Antiviral Drugs For COVID 19 market? What are the strategies for the Specific Antiviral Drugs For COVID 19 market?

For detailed insights on the major opportunities and strategies in the Specific Antiviral Drugs For COVID 19 market, request a sample here.

How does the Specific Antiviral Drugs For COVID 19 market relate to the overall economy and other similar markets?

For detailed insights on Specific Antiviral Drugs For COVID 19's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Specific Antiviral Drugs For COVID 19 industry?

For detailed insights on the mergers and acquisitions in the Specific Antiviral Drugs For COVID 19 industry, request a sample here.

What are the key dynamics influencing the Specific Antiviral Drugs For COVID 19 market growth? SWOT analysis of the Specific Antiviral Drugs For COVID 19 market.

For detailed insights on the key dynamics influencing the Specific Antiviral Drugs For COVID 19 market growth and SWOT analysis of the Specific Antiviral Drugs For COVID 19 industry, request a sample here.